WuXi AppTec Merges Formulation/Finishing Services Into API Manufacturing Division
Published: Aug 01, 2017
WuXi AppTech will merge its Pharmaceutical Development Services division into STA Pharma, a WuXi listed subsidiary that provides small molecule CRO/CMO services. The transfer adds formulation/finished drug services into STA's API and intermediate manufacturing offerings. PDS offers pre-formulation and formulation development, along with clinical trial material manufacturing and packaging services. WuXi said the merger will offer clients a complete set of manufacturing services for small molecule drugs, speeding up the development process.